Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Joseph Todisco

At a glance: Joseph Todisco is CEO at CorMedix (CRMD). Their latest SEC Form 4, filed Nov 16, 2026, reported a purchase of $391K. On file: 1 purchase line ($391K) and 1 sale line ($360K).

Disclosed holdings: about $4.3M of CRMD stock: 854,749 shares reported on their latest Form 4 (filed Nov 16, 2026), valued at the Nov 19, 2026 close of $5.04. This counts only CRMD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO at CorMedix Inc. (CRMD)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys+$12K
Total bought / sold$391K / $360K

Joseph Todisco's InsiderPrint

9 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.

InsiderPrint of Joseph Todisco: 9 trades, 2020 to 20262020: 1 buy, 0 sales2021: 0 buys, 0 sales2022: 3 buys, 0 sales2023: 2 buys, 0 sales2024: 1 buy, 0 sales2025: 0 buys, 1 sale2026: 1 buy, 0 sales

Reading this print: Mostly buys, trading about once a year, typically $51K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (8)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Stan W. ConnallyCOO · SO · 93% match
  2. James OfferdahlDirector · LAW · 93% matchTheir buys since 2023: 3 of 3 beat the S&P 500
  3. Kerrii B. AndersonDirector · LH · 93% match
  4. Douglas Michael GarisCFO · CTEV · 92% matchTheir buys since 2025: 3 of 3 beat the S&P 500
  5. Alan W. DuntonDirector · CRMD · 92% matchTheir buys since 2020: 2 of 3 beat the S&P 500

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2020

From the SEC's insider data sets: each open-market buy by Joseph Todisco, matched to how the stock did over the next 90 days against the S&P 500.

5 of 7 buys beat the S&P 500 (71%), median +8.8% vs. the index. All insider buys: 46%.

StockFiled90 days vs. S&P 500
CRMDMar 14, 2024+13.9%
CRMDSep 8, 2023-6.7%
CRMDMay 19, 2023-24.2%
CRMDNov 16, 2022+12.2%
CRMDAug 25, 2022+8.1%
CRMDMay 18, 2022+8.8%
AMRXMar 11, 2020+50.4%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 16SEC CRMDCorMedix Inc.First buy in 2 yrsPast buys 5/7 beat S&P Buy 80,000854,749 held (+10%) $4.89 $391K +3.0%
Dec 19SEC CRMDCorMedix Inc. Sell Plan 30,000509,496 held (−6%) $12.00 $360K -58.0%
  • Buy

    CEO Joseph Todisco bought $391K of CRMD at $4.89 — first open-market purchase in our records.

  • Sell

    CEO Joseph Todisco sold $360K of CRMD at $12.00 — pre-scheduled 10b5-1 plan sale.

Follow Joseph Todisco

Get one email when Joseph Todisco files a new purchase or sale. Free.

At most one email a day about Joseph Todisco, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.